Edit |   |
---|---|
Antigenic Specificity | IL3RA/CD123 (Nofetumomab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Nofetumomab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL3RA/CD123, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. 1 The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues. Label Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992. It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status. The mechanism of action in Tc-99m nm is ruled by the presence of nofetumomab, which can recognize the pancarcinoma antigen EpCAM and/or CD20/MS4A1, 2 and merpentan, that acts as a linker for the binding of technetium. |
Immunogen | n/a |
Other Names | Nofetumomab, IL3RA/CD123, 165942-79-0 |
Gene, Accession # | CAS: 165942-79-0 |
Catalog # | abx831050 |
Price | please inquire |
Order / More Info | IL3RA/CD123 (Nofetumomab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950